Monopar Therapeutics Inc
NASDAQ:MNPR
Monopar Therapeutics Inc
NASDAQ:MNPR
Price:
0.792 USD
8.91%
Market Closed
Updated:
May 7, 2024
Section:
Relative Value
There is not enough data to reliably calculate the relative value of MNPR.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
MNPR
Relative Value
Base Case
Not Available
Valuation Multiples
Multiples Across Competitors
MNPR Competitors Multiples
Monopar Therapeutics Inc Competitors
Monopar Therapeutics Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Monopar Therapeutics Inc
NASDAQ:MNPR
|
13.8m USD | 0 | -1.6 | -0.7 | -0.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
287.4B USD | 5.3 | 59.6 | 12.9 | 19.7 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
160.3B USD | 5.7 | 23.9 | 17.4 | 26 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
104.9B USD | 8 | 26.5 | 17.9 | 19.7 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
103.7B USD | 10.5 | 28.7 | 22.9 | 24 | |
| AU |
|
CSL Ltd
ASX:CSL
|
133.1B AUD | 6.2 | 35.7 | 21.6 | 26.8 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
81.7B USD | 3 | 168.7 | 6.8 | 8.9 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
46.7B USD | 6.8 | -9.9 | -10.7 | -9.1 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
32.2B USD | 3.3 | 27.6 | 14.1 | 17.7 | |
| KR |
|
Celltrion Inc
KRX:068270
|
40.8T KRW | 18.7 | 76.2 | 46.6 | 64.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
